(5/8) the FDA expanded the approval of AstraZeneca and Merck & Co.’s PARP inhibitor Lynparza (olaparib) “to include its use in combination with bevacizumab for first-line maintenance treatment of certain women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancers.” The agency’s expanded approval “applies to use of” the combination treatment “by women who achieved complete or partial response to first-line platinum-based chemotherapy, and whose cancer is associated with homologous recombination deficiency-positive status defined either by a deleterious or suspected deleterious BRCA mutation and/or genomic instability.”
